DNLI
DNLI
NASDAQ · Biotechnology

Denali Therapeutics Inc

$19.95
-1.01 (-4.82%)
Analyst Consensus
Strong Buy
26
Analysts
High
Coverage
Buy 24 92%
Hold 2 8%
Sell 0 0%
Price Target
Analyst Price Target +283.7% upside
Low Target $56.04
Average Target $76.55
High Target $105.76
Current Price $19.95
Current
$19.95
Target
$76.55
$56.04 $76.55 avg $105.76
Scenario Analysis
Bear Case
$56.04
180.9%
Low target
Base Case
$76.55
+283.7%
Avg target
Bull Case
$105.76
+430.1%
High target
Risk/Reward
2.4x
Favorable
Price in Context
52-Week High
$27.30
-26.9% from high
52-Week Low
$13.75
+45.1% from low
50-Day SMA
$20.35
-2.0% vs SMA
200-Day SMA
$21.26
-6.2% vs SMA
RSI (14)
71.7
Overbought
Target vs 52W High
$76.55
+180.4% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 39 82% $257.58 -11.6%
AMGN
Amgen Inc
Hold 42 43% $190.87 -58.6%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +115.6%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 82% $438.34 -19.9%
MRNA
Moderna Inc
Hold 31 35% $149.45 -42.4%
REGN
Regeneron Pharmaceuticals
Buy 37 70% $76.80 -91.5%
NTRA
Natera Inc
Strong Buy 30 90% $142.91 -54.4%
RVMD
Revolution Medicines Inc
Strong Buy 29 93% $114.11 -40.8%